Glaxo Sees Up to $100 Million in Initial Costs From Brexit

Updated on
  • Pharma company expects ongoing expenses in later years
  • Retesting medicines, changing licenses among needed steps

GlaxoSmithKline Plc estimates Brexit-related costs as high as 70 million pounds ($98 million) over the next two to three years as Britain’s largest drugmaker seeks to maintain a steady supply of products to patients around the world.

Glaxo expects subsequent, additional costs of roughly 50 million pounds a year, according to the London-based company’s annual report, released this week. It’s one of the most detailed accountings of potential costs of the U.K.’s departure from the European Union by any company to date.

Global drugmakers from Johnson & Johnson to AstraZeneca Plc have been flagging potential trade and regulatory hurdles that may create new financial burdens after Britain leaves the EU in March 2019. Glaxo Chief Executive Officer Emma Walmsley in October described them as “real costs” for the U.K. pharmaceutical company to manage.

Johnson & Johnson estimated in December that it could face as many as 50,000 additional tests of its products annually at a cost of almost 1 million pounds if there’s no mutual recognition of testing between the U.K. and the EU. Merck KGaA said post-Brexit tariffs could add significant costs for the company.

Read more: Why Brexit Keeps Drugmakers Up at Night

Glaxo’s expenses are tied to retesting medicines, transferring marketing authorizations in the U.K. to the European Union, changing manufacturing licenses and other steps. The estimates could change as more information becomes available, the company said.

The drugmaker said it started implementing its contingency plan in January, focusing on its supply chains. Glaxo shares rose 0.2 percent on Thursday.

“Delivering these necessary but complex changes by March 2019 will be ambitious and potentially disruptive in the short term,” Glaxo said in the annual report. “We support efforts to secure a status quo transition period to minimize disruption.”

Over the long term, Glaxo doesn’t expect Brexit to have a material impact, according to the report.

    Quotes from this Article
    Before it's here, it's on the Bloomberg Terminal.
    LEARN MORE